What is the clinical evidence from this study?

Study design: Observational. Population: Heart failure (n=16). Intervention: Cardiac contractility modulation (CCM). Primary outcome: Freedom from heart failure-related hospitalizations.

What question did this study set out to answer?

To evaluate clinical improvements in cardiac function, functional status, and hospitalization rates in patients with chronic heart failure undergoing cardiac contractility modulation therapy.

September 15, 2026European Heart Journal Supplements

CCM is linked to ~63% of high-risk heart failure patients remaining hospitalization-free at 12 months.

View Full Paper

Ask AI

Bookmark

Why the study?

Does cardiac contractility modulation (CCM) implantation improve cardiac performance and reduce hospitalizations in patients with moderate-to-severe left ventricular systolic dysfunction?

Population

16 chronic heart failure patients with an implantable cardioverter-defibrillator undergoing CCM implantation

Design

Single-center observational study

Follow-up

12 months

Key result

Cardiac contractility modulation therapy in high-risk heart failure patients resulted in 62.5% of patients remaining free from heart failure-related hospitalizations at 12 months.

Authors

RVR Valecce MDM Dadamo GIG Incampo

Discussion

Member takes

Overview

May support fewer HF hospitalizations with CCM in high-risk patients; hypothesis-generating and leaves open need for randomized confirmation.

Key Points

To evaluate clinical improvements in cardiac function, functional status, and hospitalization rates in patients with chronic heart failure undergoing cardiac contractility modulation therapy.
Conducted a single-center study of 16 patients (11 males; mean age 71 ± 10.9 years) with implantable cardioverter-defibrillators who underwent cardiac contractility modulation implantation since February 2023.
Assessed patients with baseline NYHA class III (n=10) or IV (n=6), mean LVEF of 28 ± 6.8%, and mean PASP of 43.1 ± 13.9 mmHg, with outpatient follow-ups at 3, 6, and 12 months.
Mean left ventricular ejection fraction increased from 28 ± 6.8% to 30.1 ± 8.2%, and mean pulmonary artery systolic pressure decreased from 43.1 ± 13.9 mmHg to 37.2 ± 12.8 mmHg at follow-up.
An improvement of at least one NYHA functional class occurred in four patients, while three patients had unavailable NYHA follow-up data.
A total of 62.5% of patients experienced zero heart failure-related hospitalizations during the 12 months following device implantation.

Study Design

Type

Observational (n=16)

Multicenter

Structured PICO

Does cardiac contractility modulation (CCM) implantation improve cardiac performance and reduce hospitalizations in patients with moderate-to-severe left ventricular systolic dysfunction?

Population

16 high-risk patients (NYHA class III-IV) with heart failure and an implantable cardioverter-defibrillator, followed for 12 months after cardiac contractility modulation implantation.

Exposure

Cardiac contractility modulation (CCM) implantation

Outcome

Changes in left ventricular ejection fraction (LVEF), pulmonary artery systolic pressure (PASP), NYHA class, and heart failure-related hospitalizations at 12 months

In a small single-center experience, CCM therapy in patients with moderate-to-severe heart failure was associated with improvements in LVEF, PASP, and a reduction in HF hospitalizations over 12 months.

Limitations

small sample size

Cite This Study

Valecce et al. (2026) conducted an observational in Heart failure (n=16). Cardiac contractility modulation (CCM) was evaluated on Freedom from heart failure-related hospitalizations. Cardiac contractility modulation therapy in high-risk heart failure patients resulted in 62.5% of patients remaining free from heart failure-related hospitalizations at 12 months.

synapsesocial.com/papers/6aa90187eed42882c1fc197e https://doi.org/10.1093/eurheartjsupp/suag058.325

View Full Paper

Ask AI

Bookmark

September 15, 2026European Heart Journal Supplements

CCM is linked to ~63% of high-risk heart failure patients remaining hospitalization-free at 12 months.

View Full Paper

Ask AI

Bookmark

Why the study?

Does cardiac contractility modulation (CCM) implantation improve cardiac performance and reduce hospitalizations in patients with moderate-to-severe left ventricular systolic dysfunction?

Population

16 chronic heart failure patients with an implantable cardioverter-defibrillator undergoing CCM implantation

Design

Single-center observational study

Follow-up

12 months

Key result

Cardiac contractility modulation therapy in high-risk heart failure patients resulted in 62.5% of patients remaining free from heart failure-related hospitalizations at 12 months.

Authors

RVR Valecce MDM Dadamo GIG Incampo

Discussion

Member takes

Overview

May support fewer HF hospitalizations with CCM in high-risk patients; hypothesis-generating and leaves open need for randomized confirmation.

Key Points

To evaluate clinical improvements in cardiac function, functional status, and hospitalization rates in patients with chronic heart failure undergoing cardiac contractility modulation therapy.
Conducted a single-center study of 16 patients (11 males; mean age 71 ± 10.9 years) with implantable cardioverter-defibrillators who underwent cardiac contractility modulation implantation since February 2023.
Assessed patients with baseline NYHA class III (n=10) or IV (n=6), mean LVEF of 28 ± 6.8%, and mean PASP of 43.1 ± 13.9 mmHg, with outpatient follow-ups at 3, 6, and 12 months.
Mean left ventricular ejection fraction increased from 28 ± 6.8% to 30.1 ± 8.2%, and mean pulmonary artery systolic pressure decreased from 43.1 ± 13.9 mmHg to 37.2 ± 12.8 mmHg at follow-up.
An improvement of at least one NYHA functional class occurred in four patients, while three patients had unavailable NYHA follow-up data.
A total of 62.5% of patients experienced zero heart failure-related hospitalizations during the 12 months following device implantation.

Study Design

Type

Observational (n=16)

Multicenter

Structured PICO

Does cardiac contractility modulation (CCM) implantation improve cardiac performance and reduce hospitalizations in patients with moderate-to-severe left ventricular systolic dysfunction?

Population

16 high-risk patients (NYHA class III-IV) with heart failure and an implantable cardioverter-defibrillator, followed for 12 months after cardiac contractility modulation implantation.

Exposure

Cardiac contractility modulation (CCM) implantation

Outcome

Changes in left ventricular ejection fraction (LVEF), pulmonary artery systolic pressure (PASP), NYHA class, and heart failure-related hospitalizations at 12 months

Limitations

small sample size

Cite This Study

synapsesocial.com/papers/6aa90187eed42882c1fc197e https://doi.org/10.1093/eurheartjsupp/suag058.325

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark